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Abstract  
High fructose consumption has been associated to deleterious metabolic conditions. In the 
kidney, high fructose causes renal alterations that contribute to the development of chronic 
kidney disease. Evidence suggests that dietary flavonoids have the ability to 
2 
 
prevent/attenuate risk factors of chronic diseases. This work investigated the capacity of 
(‒)-epicatechin to prevent the renal damage induced by high fructose consumption in rats. 
Male Sprague Dawley rats received 10% (w/v) fructose in the drinking water for 8 w, with 
or without supplementation with (‒)-epicatechin (20 mg/kg body weight/d) in the rat chow 
diet. Results showed that, in the presence of mild proteinuria, the renal cortex from 
fructose-fed rats exhibited fibrosis and decreases in nephrin, synaptopodin, and WT1, all 
indicators of podocyte function in association with: i) increased markers of oxidative stress; 
ii) modifications in the determinants of NO bioavailability, i.e., NO synthase (NOS) activity 
and expression; and iii) development of a pro-inflammatory condition, manifested as NF-
κB activation, and associated with high expression of TNFα, iNOS, and IL-6. Dietary 
supplementation with (‒)-epicatechin prevented or ameliorated the adverse effects of high 
fructose consumption. These results suggest that (‒)-epicatechin ingestion would benefit 
when renal alterations occur associated with inflammation or metabolic diseases. 
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mitogen-activated protein kinases; MnSOD, manganese superoxide dismutase; NF-κB; 
nuclear factor kappa-light-chain-enhancer of activated B cells; nNOS, neuronal nitric oxide 
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synthase; NOS, nitric oxide synthase; NOX, NADPH oxidase; SDS, sodium dodecyl 
sulfate; SOD, superoxide dismutase; TBARS, thiobarbituric acid reactive substances; 
TNFα, tumor necrosis factor alpha; WT1, Wilms´ tumor protein. 
 
 
Introduction  
Epidemiological studies showed an increase in the worldwide prevalence of chronic kidney 
disease [1–3]. High fructose consumption has been linked with deleterious metabolic 
changes [4]. In terms of renal modifications, data from the National Health and Nutrition 
Examination Survey (NHANES) indicate a positive association between soda 
consumption, a major source of dietary fructose, and albuminuria in humans [5]. The 
administration of fructose to rats leads to renal hypertrophy, afferent arteriolar thickening, 
glomerular hypertension, and cortical vasoconstriction, all of them contributing to the 
development of chronic kidney disease [6].  
Among several undesirable conditions developed in fructose fed-rats, elevated superoxide 
anion production seems to be a ubiquitous condition. In kidneys, an increase over 
physiological levels of superoxide anion has been related to oxidative stress, nitric oxide 
(NO) depletion, and inflammation. Furthermore, each of these conditions was associated 
to the loss of podocyte functionality, and the consequent alteration of the glomerular 
filtration barrier, which dysfunction is a major feature of kidney disease [7]. 
The beneficial effects of fruits and vegetables on human health can be in part attributed to 
their high content of flavonoids [8,9]. Increasing evidence demonstrates that dietary 
flavonoids and their metabolites contribute to the prevention and/or amelioration of the risk 
factors for cardiometabolic diseases [10–13]. The flavanol (‒)-epicatechin is one of the 
most abundant flavonoids in human diets, being present in high concentrations in apples, 
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blackberries, broad beans, cherries, grapes, pears, raspberries, cocoa, and tea [14]. 
Protective effects of (‒)-epicatechin in the kidney have been reported in pharmacological 
models of renal damage [15,16]. Dietary supplementation of (‒)-epicatechin attenuated 
renal injury in rats chronically treated with the NO synthase (NOS) inhibitor Nω-nitro-L-
arginine methyl ester (L-NAME) [15] and showed protective effects against the progression 
of mitochondrial injury in cisplatin-induced nephropathy in mice [16], but there are no 
reports on a diet-induced renal damage. 
This work presents evidence that in vivo (‒)-epicatechin supplementation was able to the 
prevent kidney fibrosis and podocyte alterations in association with the prevention or 
amelioration of the increase superoxide anion production, the alterations in NO 
metabolism, and the inflammatory manifestations in the renal cortex from fructose-fed rats.  
 
Materials and Methods 
 
Materials 
Primary antibodies for inducible nitric oxide synthase (iNOS) (#7271), p47phox (#7660), 
endothelial nitric oxide synthase (eNOS) (#654), neuronal nitric oxide synthase (nNOS) 
(#648), gp91phox (#5826), tumor necrosis factor alpha (TNFα) (#1350), manganese 
superoxide dismutase (MnSOD) (#133134), nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) p65 (#7151), heterogeneous nuclear ribonucleoprotein 
A1(hnRNP A1) (#32301), glutathione peroxidase (GPx) (#133160), Wilms´ tumor protein 
(WT1) (#192), interleukin-6 (IL-6) (#1265), nephrin (#32530), synaptopodin (#21537), 
nitrotyrosine (#32731), and β-actin (#47778), and secondary antibodies rabbit anti-goat 
IgG-HRP (#2768), mouse anti-rabbit IgG-HRP (#2357), and goat anti-mouse IgG-HRP 
(#2005) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The primary 
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antibody for copper, zinc superoxide dismutase (CuZnSOD) (AB1237) was from Chemicon 
International (Temecula, CA, USA), the primary antibody for p-eNOS Ser(1177) (#9570) 
was from Cell Signaling Technology (Boston, USA), and the primary antibody for 4-
hydroxynonenal (4-HNE) (ab46545) was from Abcam Inc. (Cambridge, MA, USA). (‒)-
Epicatechin, butylhydroxytoluene (BHT), 2-thiobarbituric acid, heparin, NADPH, glucose 6-
phosphate, reduced glutathione (GSH), N,N’-dimethyl-9,9’-biacridinium dinitrate 
(lucigenin), bovine seroalbumin, superoxide dismutase (SOD) and glutathione reductase 
were from Sigma Chemical Co. (St. Louis, MO, USA). Fructose (purity ≥ 99.5%) was 
obtained from Droguería Saporiti (Buenos Aires, Argentina). Commercial rat chow was 
from Gepsa-Feeds (Buenos Aires, Argentina). [14C] L-arginine was from PerkinElmer Life 
and Analytical Sciences (Boston, MA, USA). 
 
Animals, diets and experimental design  
All procedures were in agreement with standards for the care of laboratory animals as 
outlined in the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals (NIH Pub. No. 85-23, Revised 1996) and were approved by the Secretary of 
Science and Technology of the School of Medicine, National University of Cuyo. Male 
Sprague Dawley rats were housed under conditions of controlled temperature (21-25ºC) 
and humidity, with a 12-h light/dark cycle. Rats weighing 130 ± 20 g were randomly divided 
into the following groups (8 rats per group): control (C), receiving tap water ad libitum and 
standard rat chow diet; fructose (F), receiving 10% fructose (w/v) in the drinking water and 
standard rat chow diet; and fructose-(‒)-epicatechin (FE), receiving 10% fructose (w/v) in 
the drinking water and the standard rat chow diet supplemented with (‒)-epicatechin (20 
mg/kg body weight/d) [17]. The (−)-epicatechin provided to the rats is equivalent to 200 
mg/d for a 70-kg human, amount that is attainable through optimizing fruit and vegetable 
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intake and/or pharmacological strategies [18,19]. Food intake and beverage consumption 
were recorded throughout the experiment. Systolic blood pressure was measured at the 
beginning and at the end of the experimental period by tail plethysmography in conscious, 
prewarmed, slightly restrained rats, and recorded in a Grass Model 7 polygraph (Grass 
Instruments Co., Quincy, MA, USA). Four days before euthanasia, rats were placed in 
metabolic cages for 24 h for urine collection. After 8 w on the respective treatments, and 
after overnight fast, rats were weighed and anesthetized with ketamine (50 mg/kg of body 
weight) and acepromazine (1 mg/kg body weight). Blood was collected from the abdominal 
aorta into heparinized tubes and plasma was obtained after centrifugation (600 x g, 15 
min, 4°C). Blood plasma samples were frozen at -80°C. Kidneys were excised immediately 
and processed for histological, immunohistochemical, and biochemical determinations. 
 
Sample processing 
For each animal, a portion of renal cortex was separated and fixed in phosphate-buffered 
10% (v/v) formaldehyde (pH: 7.2) for further histological and immunohistochemical 
analysis. Another section of the renal cortex was excised and homogenized in PBS (7.6 
mM KH2PO4, 42.4 mM K2HPO4, 150 mM NaCl, pH: 7.4), and centrifuged at 600 x g for 20 
min at 4°C. Supernatants were used for the measurement of enzyme activities and for 
thiobarbituric acid reactive substances (TBARS) determination. For the determination of 
NADPH-dependent superoxide anion production, supernatants were centrifuged at 10000 
x g for 20 min at 4°C to obtain mitochondria-free homogenates. For Western Blot 
determinations, renal cortex was homogenized in lysis buffer (150 mM NaCl, 50 mM 
Trizma-HCl, 1% (v/v) NP-40, pH: 8.0) in the presence of protease and phosphatase 
inhibitors, and centrifuged at 600 x g for 20 min. The supernatant was collected and 
defined as total fraction tissue. Cytosolic and nuclear fractions of kidney cortex were 
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isolated as described previously [20]. Protein content was measured by the Lowry method 
[21]. 
 
Biochemical determinations 
All biochemical determinations were performed using commercially available kits: plasma 
glucose, triglycerides, total cholesterol and urinary protein levels (GTLab, Rosario, 
Argentina), and uric acid levels in plasma and creatinine levels in plasma and urine 
(Wiener Lab., Argentina). All the determinations were performed following the 
manufacturers’ protocols.  
 
TBARS determination 
The assay was based on a previously described method [22]. Briefly, samples were mixed 
with 3% (w/v) sodium dodecyl sulfate (SDS), 0.1 N HCl, 10% (w/v) phosphotungstic acid, 
and 0.7% (w/v) 2-thiobarbituric acid, and heated for 45 min in boiling water. TBARS were 
extracted with 2 ml of n-butanol and detected fluorometrically (λex: 515 nm; λem: 555 nm). 
1, 1, 3, 3-Tetramethoxypropane was used to prepare the standard of malondialdehyde. 
The results were expressed as nmoles of TBARS (malondialdehyde equivalents)/mg 
protein. 
 
Determination of NADPH-dependent superoxide anion production 
Lucigenin-enhanced chemiluminescence was measured in renal cortex mitochondria-free 
homogenates according to Li et al [23]. Briefly, samples were added to vials containing 1 
ml of 50 mM potassium phosphate at 37ºC, pH: 7.4 containing lucigenin and NADPH (5 
μM and 40 μM final concentrations, respectively) in the absence or the presence of SOD 
(200 U/ml). Light emission was measured every 10 s for 10 min using a LKB Wallac 1209 
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Rackbeta Liquid Scintillation Counter (Turku, Finland) in the chemiluminescence mode. 
Results were expressed as the difference between the areas under the curve in the 
absence and in the presence of SOD, which represents the amount of superoxide anion 
produced. 
Western Blot analysis 
Renal cortex homogenates were added with a 2X solution of sample buffer (62.5 mM Tris-
HCl, pH: 6.8 containing 2% (w/v) SDS, 25% (w/v) glycerol, 5% (v/v) β-mercaptoethanol, 
and 0.01% (w/v) bromophenol blue) and heated at 95°C for 2 min. Sample aliquots 
containing 30 μg of protein were separated by reducing 10% (w/v) polyacrylamide gel 
electrophoresis and electroblotted to polyvinylidenedifluoride membranes. Colored 
molecular weight standards (GE Healthcare, Piscataway, NJ, USA) were run 
simultaneously. Membranes were blotted for 2 h in 5% (w/v) nonfat milk and incubated 
overnight in the presence of the corresponding primary antibody (1:1000 dilution in PBS). 
After a subsequent incubation for 90 min at room temperature in the presence of the 
corresponding HRP-conjugated secondary antibody (1:5000 dilution in PBS), complexes 
were visualized by chemiluminescence. Films were scanned and a densitometric analysis 
was performed using Image J (National Institute of Health, Bethesda, Maryland, USA). 
Total and cytosolic extract band densities were normalized to the β-actin content. Bands 
from the nuclear fractions were normalized to the hnRNP A1 content. 
 
Determinations of catalase (CAT), glutathione peroxidase (GPx), and superoxide 
dismutase (SOD) activities  
Enzymes activities were measured in renal cortex homogenates. CAT activity was 
determined spectrophotometrically following the consumption of H2O2 at 240 nm. Results 
were expressed as μmol H2O2/mg protein.min [24,25]. GPx activity was determined 
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spectrophotometrically following the enzymatic oxidation of NADPH at 340 nm in the 
presence of 1 mM GSH, 1 mM NaN3, 0.15 mM NADPH, and 0.25 U/ml glutathione 
reductase. Results were expressed as μmol GSH oxidized/mg protein.min [26]. SOD 
activity was spectrophotometrically determined following the inhibition of the formation of 
adrenochrome. One unit of SOD is defined as the amount of enzyme that causes a 50% 
inhibition of the rate of this reaction. As CuZnSOD is inhibited by cyanide, the reactions 
were carried out in the absence or in the presence of 4 μM KCN, to obtain total SOD or 
MnSOD activities, respectively. CuZnSOD activity was calculated as the difference 
between total and MnSOD activities. Results were expressed as units/mg protein [27]. 
 
Determination of nitric oxide synthase (NOS) activity  
NOS activity was measured using [14C] L-arginine as substrate in renal cortex slices [28]. 
NO production, measured as pmol of [14C] L-citrulline, was normalized to the weight of the 
tissue slices incubated with the substrate during 30 min. Results were expressed as pmol 
[14C] L-citrulline/g.min. 
 
Histological and immunochemical analysis of the kidney 
Fixed kidney cortex were embedded in paraffin, and 3 micron sections were cut and 
stained with Sirius Red as described [29].  Histological evaluations were performed using a 
light microscope Nikon E400 (Nikon Instrument Group, Melville, NY, USA). 
Immunohistochemistry was performed with antibodies against IL-6 (1:100 in PBS), nephrin 
(1:400 in PBS), WT1 (1:400 in PBS) and synaptopodin (1: 300 in PBS). Staining was 
performed with a commercially modified avidin-biotin-peroxidase complex and hematoxylin 
counterstaining as described [30]. Immunostaining is quantified as percentage of positive 
staining per area from 20 random images viewed at x400 magnification. Measurements 
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were made using an image analyzer, Image-Pro Plus version 4.5 for Windows (Media 
Cybernetics, LP, Silver Spring, MD, USA). 
 
Statistical analysis 
Results are shown as mean ± SEM. Except for histology, data were analyzed by one-way 
analysis of variance (ANOVA) using StatView 5.0 (SAS Institute, Cary, NC, USA), and 
Fisher’s significance difference test was used to examine differences between group 
means. Histological data were analyzed by nonparametric Kruskal-Wallis test using 
absolute values processed through GraphPad Prism 5.01 (GraphPad Software, Inc. San 
Diego, CA, USA), and Dunn´s multiple comparison test. A value of p < 0.05 was 
considered statistically significant.  
 
Results 
Metabolic parameters are shown in Table 1. Body and kidney weights were similar among 
the three experimental groups. The two groups receiving fructose showed higher (43-47%, 
p < 0.05) daily liquid intake and lower (29-18%, p < 0.05) daily food intake compared with 
C. One reason for the increased liquid intake in the animals receiving fructose in the 
beverage could be the palatability of the fluid  [31]. The decrease in the amount of solid 
diet consumed suggests a strategy to control the overall caloric intake [32]. Rats from F 
presented a systolic blood pressure 16 and 10 mmHg higher respect to C and FE (p < 
0.05), respectively. No differences were found in plasma glucose and total cholesterol 
levels among the three groups. Rats from F presented higher plasma triglyceride levels 
respect to C (1.7-fold increase, p < 0.05); while FE rats presented values similar to C. No 
significant differences were found in uric acid and creatinine levels in serum among the 
three groups. Diuresis was higher (approximately 4.0-fold increase, p < 0.05), in F and FE 
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compared to C. The amount of excreted protein was higher in F compared to C (71%, p < 
0.05) and FE (37%, p < 0.05) (Table 1).  
Collagen deposition, an index of fibrosis, was evaluated by Sirius Red staining in renal 
cortex tissue (Figure 1). Interstitial and perivascular collagen deposition was higher in F 
than in C (3.0-fold increase) indicating a high degree of fibrosis. FE showed a significantly 
lower collagen deposition, i.e. only 1.0-fold increase over C value. The expression of 
nephrin, one of the structural components of kidney glomerular slit diaphragms, was 
significantly lower in F respect to C (Figure 2A). Synaptopodin and WT1, both recognized 
markers of glomerular epithelial cells (podocytes), were also lower in F respect to C 
(Figure 2B and C). Taken together, these changes in protein expression demonstrated a 
podocyte injury in F. In FE, the expression of the three proteins was increased respect to F 
(p < 0.05) tending to reach C values.  
The content of TBARS, nitrotyrosine, and 4-HNE protein adducts in renal cortex were 
measured to evaluate oxidative stress. F rats showed higher values compared to C in the 
three parameters (29%, 48%, and 33%; p < 0.05 for TBARS, nitrotyrosine, and 4-HNE 
protein adducts, respectively) (Figure 3A, D, and F). In FE the values of the three 
parameters were similar to those measured in C. Tissue capacity to produce superoxide 
anion was estimated measuring the SOD-inhibitable chemiluminiscence of lucigenin in the 
presence of NADPH. Chemiluminiscence was higher in F respect to C (107%; p < 0.05), 
and in FE it was similar to C (Figure 3B). In terms of NADPH oxidase (NOX) protein 
subunits, the expression of the membrane catalytic subunit gp91phox was higher in F and 
FE respect to C (43% and 48% respectively; p < 0.05), while the expression of the 
activator subunit p47phox was higher in F compared with C and FE (47% and 28% 
respectively; p < 0.05) (Figure 4). 
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The activities of the antioxidant enzymes SOD, GPx, and CAT were measured in renal 
cortex as indexes of the capacity to cope with the increase in superoxide anion and 
hydrogen peroxide production. The activity and the expression of the cytosolic isoform 
(CuZnSOD) were higher in F compared to C (30% and 79%; p < 0.05). In FE, CuZnSOD 
activity and expression showed values lower than in F, but did not reach statistical 
significance (p < 0.08). No differences among the three groups were observed for the 
activity and expression of the mitochondrial isoform (MnSOD). GPx activity was higher in 
the renal cortex from F respect to C (32%; p < 0.05), and was similar to C values in FE. 
CAT activity was similar among three groups (Figure 5). 
In terms of NO metabolism in renal cortex, NOS activity was higher in F and FE compared 
to C (14% and 40%, respectively, p < 0.01). nNOS protein levels in renal cortex 
homogenates, were significantly lower in F respect to C and FE (39% and 41%, 
respectively, p < 0.05). eNOS protein expression was similar among the three 
experimental groups, but eNOS phosphorylation (Ser-1177) were significantly higher in F 
and FE respect to C (41% and 42%, respectively, p < 0.05) (Figure 6). 
In order to evaluate the occurrence of an inflammatory condition, the cytosolic and nuclear 
distribution of the transcription factor NF-κB subunit p65, and the expression of 
downstream pro-inflammatory targets TNFα, iNOS, and IL-6 were measured in renal 
cortex. The ratio nuclear/cytosolic p65 was higher in F respect to C and FE (31% and 27% 
respectively; p < 0.05). TNFα protein level in F was higher in C and FE (47% and 53% 
respectively; p < 0.05). iNOS protein content in renal cortex was higher in F respect to C 
and FE (9.0- and 2.6-fold increase, respectively; p < 0.05) (Figure 7). IL-6 level in F was 
higher respect to C and FE (7.0- and 1.0-fold increase respectively; p < 0.05) (Figure 8). 
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Discussion 
Fructose induced deleterious kidney changes that were associated with oxidative stress, 
alterations in NO metabolism, and a pro-inflammatory condition. All these adverse effects 
were absent or significantly reduced when the rat diets were supplemented with (‒)-
epicatechin. These results are in line with our previous work [17,19] showing that (‒)-
epicatechin prevents dysfunctional changes associated to high fructose treatment in the 
cardiovascular system, liver, and fat tissue.  
Development of renal functional changes in fructose-fed rats is highly dependent on the 
amount of fructose administered and the time of exposure. In agreement with a previous 
report [6], under the experimental conditions used (10% (w/v) of fructose in the beverage 
for 8 w), renal functions were mildly affected. Even when the kidneys from F rats disposed 
normally nitrogenous waste products, an incipient loss of control of urinary protein 
excretion was observed. This renal condition, could be associated to both, interstitial and 
perivascular fibrosis, and the decrease of specific podocyte proteins, even no glomerular 
fibrosis was observed. This incipient damage to kidney was prevented by (‒)-epicatechin. 
The decrease in fibrosis appears as a result of the attenuation in the pro-inflammatory 
condition. Meanwhile, the protective effects of (‒)-epicatechin observed in podocytes could 
be related with alternative mechanisms that could occur in parallel or somehow related to 
inflammation, e.g. regulation of insulin signaling. In this regard, it has been reported that 
fructose consumption affects podocytes through an impairment of insulin signaling [33, 
34], and that (‒)-epicatechin improves insulin signaling in liver and adipose tissue [17].  
In terms of mechanisms, both the high NADPH-dependent superoxide anion production, 
and the increased levels of oxidative damage observed in fructose-fed rats agree with 
previous observations in kidney [7, 35] and in other tissues [17, 19, 36]. The action of (‒)-
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epicatechin preventing the increases in oxidative stress, suggests an antioxidant action. 
(‒)-Epicatechin shares with other flavonoids the ability to scavenge free radicals being 
effective ex vivo at concentrations of 25-100 μM [37–39]. However, due to the sub 
micromolar concentration of this compound found in plasma and in other tissues [40, 41], 
the possibility that (‒)-epicatechin could scavenge radicals in vivo with a physiological 
relevance is unlikely [9, 42]. Then, indirect antioxidant mechanisms, operative at the 
amount of (‒)-epicatechin expected to be present in kidneys, must be proposed to explain 
the observed effects [43, 44]. One mechanism could be the regulation of the source of 
superoxide anion production in renal cortex. In the kidney, NOXs are a major source of 
both superoxide anion and hydrogen peroxide [45]. In this work, we observed that fructose 
treatment increased the protein expressions of the NOX2 subunits gp91phox and p47phox. 
(‒)-Epicatechin partially prevented the overexpression of p47phox and this prevention would 
result in a normal superoxide anion production. 
The production of superoxide anion is tightly regulated given its role in signaling pathways 
and the need to prevent uncontrolled oxidation of cell components [46]. The observed 
increased activity and expression of the CuZnSOD in F would reflect an adaptive 
mechanism against increased superoxide anion cellular levels. Superoxide metabolism by 
SOD leads to an increase in hydrogen peroxide production, which explain the increased 
GPx activity that can occur via posttranslational modifications, e.g. phosphorylation at 
activators sites [47]. The inhibition by (‒)-epicatechin of the excessive superoxide anion 
production triggered by fructose may explain the partial prevention of the increases in 
CuZnSOD and GPx activities. 
In terms of NO metabolism, in F rats NOS activation would justify a moderate increase of 
NO production; at the same time superoxide anion production could be doubled. These 
altered rates of production, and the high rate of the reaction between NO and superoxide 
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anion [48, 49] would result in a lower overall NO bioavailability that will compromise normal 
kidney function. In addition, being peroxynitrite, the product of the reaction between NO 
and superoxide anion, a strong oxidant, it would further contribute to the observed 
oxidative damage. In the rats receiving (‒)-epicatechin, a higher NO bioavailability would 
result of the moderate increase in NOS, and mostly by a return to normal values of 
superoxide anion production determinants. The restoration of a physiologically appropriate 
NO bioavailability by (‒)-epicatechin associated to normal tissue function has been 
previously described in other experimental models and tissues [19, 50, 51]. 
Impaired oxidant and NO metabolisms can lead to an altered cell redox status, triggering 
or amplifying inflammatory events [17, 52]. The occurrence of renal oxidative stress in 
fructose-fed rats could be the cause for the activation of the redox-sensitive and pro-
inflammatory NF-κB transcription factor. Furthermore, the observed high levels of the pro-
inflammatory agents, i.e. TNFα, iNOS and IL-6, are indicative that fructose consumption 
led to an inflammatory condition in the kidney. (‒)-Epicatechin supplementation mitigated 
fructose-mediated inflammation by decreasing the expression of the measured cytokines 
and proteins. These results in kidney are in agreement with those found in rats subjected 
to the same fructose overload showing that (‒)-epicatechin mitigated NF-κB activation, and 
TNFα, and monocyte chemoattractant protein-1 (MCP-1) expressions in both adipose 
tissue and liver [17]. In addition, in 3T3-L1 adipocytes in culture (‒)-epicatechin supressed 
the TNFα-mediated activation of NF-κB, activator protein-1 (AP-1), and the mitogen-
activated protein kinases (MAPKs) [44]. Moreover, direct evidence showing that (‒)-
epicatechin acts decreasing NF-κB activation in vivo has been recently published [53]. 
Molecular mechanisms involved in the effects of (‒)-epicatechin on NF-κB activation could 
be either, secondarily to an inhibition of oxidant production, and/or through specific 
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interactions of (‒)-epicatechin with NF-κB proteins p50 and p65, preventing their binding to 
NF-κB sites in the promoter of target genes [54, 55].  
It is well known that (‒)-epicatechin is extensively metabolized after ingestion, allowing 
very low concentrations of the parent compound (< 500 nM) in human blood after the 
consumption of flavanol-rich foods. It is very likely that metabolites of (‒)-epicatechin are 
the molecular effectors of the observed effects. For example, 3’- and 4’-O-methyl-(‒)-
epicatechin were postulated to interact and inhibit NOX activity in endothelial cells [56], 
and 3’- and 4’-O-methyl-(‒)-epicatechin-5/7-sulfates are major metabolites present in 
plasma after (‒)-epicatechin administration to humans [40, 41]. 
Integrating the present results, we propose that the oxidative stress triggered by NOX 
overexpression and superoxide anion production increase is one of the main underlying 
causes of the incipient kidney changes associated with high fructose intake. In the long 
term, this would lead to overt kidney dysfunction. This hypothesis is supported by results 
showing that: i) a fructose-induced oxidant production, especially superoxide anion, 
participates in podocyte injury in rodents [7]; and ii) fructose activates the superoxide 
anion/p38/MAPK/TXNIP/NLRP3 inflammasome pathway resulting in glomerular podocyte 
injury [57]. Consequently, a down-regulation of NOX, as is that observed following (‒)-
epicatechin supplementation, could be a central event in the control of fructose-associated 
and inflammation-mediated kidney damage. 
Taken as a whole, dietary supplementation with (‒)-epicatechin mitigates renal 
modifications observed in fructose-fed rats through the modulation of oxidant production, 
improvement of NO bioavailability, and down-regulation of redox-sensitive pro-
inflammatory pathways. Overall (‒)-epicatechin emerges as a bioactive which 
consumption, as part of a flavanol-rich diet, could help to prevent the renal alterations 
found in subjects suffering metabolic and other inflammatory diseases.  
17 
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Table 1. Effects of (‒)-epicatechin on metabolic and renal function parameters and 
systolic blood pressure of fructose-fed rats 
 
Parameter                C         F       FE 
 
Body weight (g)   393 ± 17 365 ± 12 389 ± 15 
Kidney weight (g)    2.5 ± 0.1  2.4 ± 0.1  2.6 ± 0.1 
Liquid intake (ml/24 h)      51 ± 4   73 ± 3*   75 ± 3* 
Food intake (g/24 h)     28 ± 1   20 ± 1*   23 ± 2* 
Systolic blood pressure (mmHg) 129 ± 3            145 ± 3* 135 ± 2† 
Plasma glucose (mg/dl)    90 ± 2   85 ± 2   90 ± 2 
Plasma cholesterol (mg/dl)   43 ± 2      45 ± 3   47 ± 4 
Plasma triglycerides (mg/dl)   55 ± 4  148 ± 25*          85 ± 7† 
Serum uric acid (mg/dl)   0.8 ± 0.1  0.7 ± 0.1  0.7 ± 0.1 
Serum creatinine (mg/dl)   0.7 ± 0.1  0.7 ± 0.1  0.7 ± 0.1 
Diuresis (ml/24 h)       6 ± 1  28 ± 3*  30 ± 3* 
Proteinuria (mg/mg creatinine)  2.4 ± 0.4  4.1 ± 0.6*  3.0 ± 0.2† 
 
C: control, F: fructose, and FE: fructose-(‒)-epicatechin groups. Values are expressed as 
means ± SEM; n = 8 animals/group. *p < 0.05 respect to C, †p < 0.05 respect to F. 
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Figure captions 
Figure 1: Effects of dietary (‒)-epicatechin on collagen deposition in the renal cortex 
from fructose-fed rats. (A-C) Representative images for renal cortex collagen III staining 
using Sirius Red in the different experimental groups. (D) After quantification of collagen III 
staining degree in samples from C: control, F: fructose, and FE: fructose-(‒)-epicatechin. 
Values are expressed as means ± SEM; n = 8 animals/group. *p < 0.01 respect to C, ‡p < 
0.01 respect to C and F.  
 
Figure 2: Effects of dietary (‒)-epicatechin on nephrin, synaptopodin and WT1 
immunostaining in the renal cortex from fructose-fed rats. (A-C) Representative 
images of proteins nephrin, synaptopodin and WT1 in renal cortex from the different 
experimental groups. (D) After quantification of the three proteins in samples from C: 
control, F: fructose, and FE: fructose-(‒)-epicatechin. Values are expressed as means ± 
SEM; n = 8 animals/group.  *p < 0.01 respect to C, †p < 0.05 respect to F, ‡p < 0.01 
respect to C and F.  
 
Figure 3: Effects of dietary (‒)-epicatechin on the levels of TBARS and nitrotyrosine 
and 4-HNE protein adducts and on NADPH-dependent superoxide anion production 
in the renal cortex from fructose-fed rats. (A) TBARS were measured in renal cortex 
homogenates, (B) NADPH-dependent superoxide anion production was measured as 
SOD-inhibitable lucigenin chemiluminescence in mitochondria-free renal cortex 
homogenates, (C-D) nitrotyrosine protein adducts were measured by Western Blot in renal 
cortex homogenates (Left panel shows a representative image), and (E-F) 4-HNE protein 
adducts were measured by Western Blot in the cytosolic fraction of renal cortex 
homogenates (Left panel shows a representative image). C: control, F: fructose, FE: 
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fructose-(‒)-epicatechin. Values are expressed as means ± SEM; n = 8 animals/group. *p 
< 0.05 respect to C, †p < 0.05 respect to F. 
 
Figure 4: Effects of dietary (‒)-epicatechin on gp91phox and p47phox expression in the 
renal cortex from fructose-fed rats. (A) gp91phox and (B) p47phox protein levels were 
measured by Western Blot in renal cortex homogenates from C: control, F: fructose, FE: 
fructose-(‒)-epicatechin. Values are expressed as means ± SEM; n = 8 animals/group. *p 
< 0.05 respect to C, †p < 0.05 respect to F. 
 
Figure 5: Effects of dietary (‒)-epicatechin on the activity and expression of SOD 
and GPx, and the activity of CAT in the renal cortex from fructose-fed rats. (A) SOD 
activity  and (B) expression, (C) GPx activity and (D) expression and (E) CAT activity were 
measured in renal cortex homogenates from C: control, F: fructose, FE: fructose-(‒)-
epicatechin. Values are expressed as means ± SEM; n = 8 animals/group. *p < 0.05 
respect to C. 
 
Figure 6: Effects of dietary (‒)-epicatechin on NOS activity, nNOS and eNOS 
expression and eNOS phosphorylation in the renal cortex from fructose-fed rats. (A) 
NOS activity measured in renal cortex slices. (B)  nNOS, (C) eNOS protein levels, and (D) 
eNOS phosphorylation in Ser(1177) were measured in renal cortex homogenates from C: 
control, F: fructose, FE: fructose-(‒)-epicatechin. Values are expressed as means ± SEM; 
n = 8 animals/group. *p < 0.05 respect to C, †p < 0.05 respect to F, ‡p < 0.05 respect to C 
and F.  
Figure 7: Effects of dietary (‒)-epicatechin on the ratio nuclear/cytosolic p65 and on 
TNFα and iNOS expression in the renal cortex from fructose-fed rats. (A) The ratio 
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nuclear/cytosolic p65, (B) TNFα and (C) iNOS expressions were measured in renal cortex 
homogenates from C: control, F: fructose, FE: fructose-(‒)-epicatechin. Values are 
expressed as means ± SEM; n = 8 animals/group. *p < 0.05 respect to C, †p < 0.05 
respect to F. 
Figure 8: Effects of dietary (‒)-epicatechin on IL-6 inmunostaining in the renal cortex 
from fructose-fed rats. (A-C) Representative images for IL-6 in the renal cortex from the 
different experimental groups. (D) After quantification of IL-6 expression immunostaining in 
C: control, F: fructose, and FE: fructose-(‒)-epicatechin. Values are expressed as means ± 
SEM; n = 8 animals/group. *p < 0.01 respect to C, ‡p < 0.01 respect to C and F.  
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Highlights  
(‒)-Epicatechin reduced alterations in podocytes induced by fructose in rats. 
(‒)-Epicatechin reduced oxidative stress in renal cortex of fructose-fed rats. 
(‒)-Epicatechin restored NO bioavailability in renal cortex of fructose-fed rats.  
(‒)-Epicatechin ameliorated inflammation in renal cortex of fructose-fed rats.  
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